In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...

Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...

While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...

US stocks closed in the red on Wednesday after the Federal Reserve said it would bide its time before making any further ...

Boston Properties (NYSE:BXP) reported its fourth-quarter 2024 earnings, revealing a significant miss on earnings per share ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Discover which stocks are splitting, the ratio, and split ex-date with the latest information from EDGAR® Online LLC. Data provided by and © 2024 EDGAR® Online LLC ...

ANALYSISUS tech stock tumble highlights risk of market reliance on megacaps Turbulence in some of the biggest tech names is reminding investors of one of the major risks to the U.S. stock ...

2-Year U.S. Treasury Note Continuous Contract $102.914 0.027 0.03% 5-Year U.S. Treasury Note Continuous Contract $106.602 0.102 0.10% 10-Year U.S. Treasury Note Continuous Contract $109.203 0.172 ...